Collegium Pharmaceutical Inc banner

Collegium Pharmaceutical Inc
NASDAQ:COLL

Watchlist Manager
Collegium Pharmaceutical Inc Logo
Collegium Pharmaceutical Inc
NASDAQ:COLL
Watchlist
Price: 33.07 USD 3.38% Market Closed
Market Cap: $1B

Multiples-Based Value

The Multiples-Based Value for Collegium Pharmaceutical Inc (COLL) under the Base Case is 59.36 USD. Compared with the current market price of 33.07 USD, the stock appears Undervalued by 44%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

COLL Multiples-Based Value
Base Case
59.36 USD
Undervaluation 44%
Multiples-Based Value
Price $33.07
Worst Case
Base Case
Best Case

Multiples Across Competitors

COLL Competitors Multiples
Collegium Pharmaceutical Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Collegium Pharmaceutical Inc
NASDAQ:COLL
1B USD 1.3 16.7 3.6 8
US
Eli Lilly and Co
NYSE:LLY
869B USD 13.3 42.1 28.4 30.3
US
Johnson & Johnson
NYSE:JNJ
588.6B USD 6.2 22 15.2 18.7
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.4 11.5 13
UK
AstraZeneca PLC
LSE:AZN
227.8B GBP 5.2 29.9 16.5 23.3
US
Merck & Co Inc
NYSE:MRK
297.7B USD 4.6 16.3 10.1 12.3
CH
Novartis AG
SIX:NOVN
229.9B CHF 5.3 21.4 13.2 17
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
US
Pfizer Inc
NYSE:PFE
159.7B USD 2.6 20.5 7.8 10.4
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.3 10 7.5 8.8
US
Bristol-Myers Squibb Co
NYSE:BMY
122.1B USD 2.5 17.3 7.3 9
P/E Multiple
Earnings Growth PEG
US
Collegium Pharmaceutical Inc
NASDAQ:COLL
Average P/E: 21.6
16.7
37%
0.5
US
Eli Lilly and Co
NYSE:LLY
42.1
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
22
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.4
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.9
26%
1.1
US
Merck & Co Inc
NYSE:MRK
16.3
14%
1.2
CH
Novartis AG
SIX:NOVN
21.4
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
20.5
22%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
10
1%
10
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Collegium Pharmaceutical Inc
NASDAQ:COLL
Average EV/EBITDA: 45.1
3.6
0%
N/A
US
Eli Lilly and Co
NYSE:LLY
28.4
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.5
13%
1.3
US
Merck & Co Inc
NYSE:MRK
10.1
3%
3.4
CH
Novartis AG
SIX:NOVN
13.2
5%
2.6
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
-9%
N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.5
1%
7.5
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-10%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett